These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 15870435)

  • 1. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
    Cappuzzo F; Hirsch FR; Rossi E; Bartolini S; Ceresoli GL; Bemis L; Haney J; Witta S; Danenberg K; Domenichini I; Ludovini V; Magrini E; Gregorc V; Doglioni C; Sidoni A; Tonato M; Franklin WA; Crino L; Bunn PA; Varella-Garcia M
    J Natl Cancer Inst; 2005 May; 97(9):643-55. PubMed ID: 15870435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
    Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
    J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
    Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
    J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?
    Kaye FJ
    J Natl Cancer Inst; 2005 May; 97(9):621-3. PubMed ID: 15870427
    [No Abstract]   [Full Text] [Related]  

  • 5. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
    Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
    Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
    Hirsch FR; Varella-Garcia M; Bunn PA; Franklin WA; Dziadziuszko R; Thatcher N; Chang A; Parikh P; Pereira JR; Ciuleanu T; von Pawel J; Watkins C; Flannery A; Ellison G; Donald E; Knight L; Parums D; Botwood N; Holloway B
    J Clin Oncol; 2006 Nov; 24(31):5034-42. PubMed ID: 17075123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
    Argiris A; Hensing T; Yeldandi A; Patel S; Raji A; Sturgis C; Masters G; Gooding W; Pins M; Kolesar J
    J Thorac Oncol; 2006 Jan; 1(1):52-60. PubMed ID: 17409827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
    Cappuzzo F; Ligorio C; Jänne PA; Toschi L; Rossi E; Trisolini R; Paioli D; Holmes AJ; Magrini E; Finocchiaro G; Bartolini S; Cancellieri A; Ciardiello F; Patelli M; Crino L; Varella-Garcia M
    J Clin Oncol; 2007 Jun; 25(16):2248-55. PubMed ID: 17538169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib.
    Buckingham LE; Coon JS; Morrison LE; Jacobson KK; Jewell SS; Kaiser KA; Mauer AM; Muzzafar T; Polowy C; Basu S; Gale M; Villaflor VM; Bonomi P
    J Thorac Oncol; 2007 May; 2(5):414-22. PubMed ID: 17473657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.
    Azuma K; Okamoto I; Kawahara A; Taira T; Nakashima K; Hattori S; Kinoshita T; Takeda M; Nakagawa K; Takamori S; Kuwano M; Ono M; Kage M
    J Thorac Oncol; 2012 Jan; 7(1):122-7. PubMed ID: 21892099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
    Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
    J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
    J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
    Han SW; Hwang PG; Chung DH; Kim DW; Im SA; Kim YT; Kim TY; Heo DS; Bang YJ; Kim NK
    Int J Cancer; 2005 Jan; 113(1):109-15. PubMed ID: 15386420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
    Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
    J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
    Loprevite M; Tiseo M; Chiaramondia M; Capelletti M; Bozzetti C; Bortesi B; Naldi N; Nizzoli R; Dadati P; Kunkl A; Zennaro D; Lagrasta C; Campanini N; Spiritelli E; Camisa R; Grossi F; Rindi G; Franciosi V; Ardizzoni A
    Clin Cancer Res; 2007 Nov; 13(21):6518-26. PubMed ID: 17975165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.